Treatment of High or Very High Risk Myelofibrosis in Patients Not Eligible for Transplant
In primary myelofibrosis, risk stratification directly shapes treatment choices. For patients classified as high or very high risk who are not candidates for allogeneic stem cell transplant, selecting the appropriate first-line systemic therapy is the central clinical decision.
Clinical Scenario
This protocol addresses patients with high or very high risk myelofibrosis who are not transplant eligible. Both the risk category and the absence of transplant candidacy define the population and drive the treatment pathway.
Treatment Approach — Partial Overview
First-line management in this setting centres on an oral therapy from the JAK inhibitor class, selected to maximise control of spleen enlargement and disease-related symptoms.
The complete regimen, dosing approach, and decision algorithm are available in the full protocol.
Treatment Goals
- Significant reduction in spleen volume
- Substantial reduction in symptom burden within approximately 8 weeks
References
- High/very high risk
- Not Transplant Eligible
- 1st line JAK inhibitor to maximise spleen and symptom response
- Ruxolitinib is an oral JAK1/JAK2 inhibitor indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with PMF, post-ET MF and post-PV MF.
- Around 80% of patients treated with ruxolitinib experience ≥10% reduction in spleen volume; primary resistance is rare.
- Ruxolitinib can elicit rapid symptomatic responses, with nearly 40%–50% of patients achieving a 50% reduction in symptom burden in around 8 weeks when treated with adequate dose density.
View source ↗